186 related articles for article (PubMed ID: 23274669)
1. Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.
Ma L; Cai YJ; Yu L; Feng JY; Wang J; Li C; Niu JQ; Jiang YF
Antimicrob Agents Chemother; 2013 Mar; 57(3):1304-11. PubMed ID: 23274669
[TBL] [Abstract][Full Text] [Related]
2. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.
Li CZ; Hu JJ; Xue JY; Yin W; Liu YY; Fan WH; Xu H; Liang XS
World J Gastroenterol; 2014 Jul; 20(28):9486-96. PubMed ID: 25071343
[TBL] [Abstract][Full Text] [Related]
3. Functional restoration of CD56
Chen T; Zhu L; Shi A; Ding L; Zhang X; Tan Z; Guo W; Yan W; Han M; Jia J; Luo X; Schuppan D; Ning Q
Hepatol Int; 2017 Sep; 11(5):419-428. PubMed ID: 28639033
[TBL] [Abstract][Full Text] [Related]
4. Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir.
Zhang L; Wang Q; Zhao P; Hu X; Jiang Y
Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):514-23. PubMed ID: 24773272
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment.
Li C; Ji H; Cai Y; Ayana DA; Lv P; Liu M; Jiang Y
J Interferon Cytokine Res; 2013 Oct; 33(10):612-8. PubMed ID: 23697556
[TBL] [Abstract][Full Text] [Related]
6. Recovery of circulating CD56
Liu N; Liu B; Zhang L; Li H; Chen Z; Luo A; Chen M; Peng M; Yin W; Ren H; Hu P
Int Immunopharmacol; 2018 Sep; 62():59-66. PubMed ID: 29990695
[TBL] [Abstract][Full Text] [Related]
7. TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B.
Lai Q; Ma S; Ge J; Huang Z; Huang X; Jiang X; Li Y; Zhang M; Zhang X; Sun J; Abbott WG; Hou J
PLoS One; 2014; 9(2):e88475. PubMed ID: 24551107
[TBL] [Abstract][Full Text] [Related]
8. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
[TBL] [Abstract][Full Text] [Related]
9. Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment.
Lv G; Ying L; Ma WJ; Jin X; Zheng L; Li L; Yang Y
Virol J; 2010 Aug; 7():207. PubMed ID: 20807412
[TBL] [Abstract][Full Text] [Related]
10. Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
Yang X; Li J; Liu J; Gao M; Zhou L; Lu W
Medicine (Baltimore); 2017 Jun; 96(23):e7064. PubMed ID: 28591041
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
[TBL] [Abstract][Full Text] [Related]
12. Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B.
Li J; Jia M; Liu Y; She W; Li L; Wang J; Jiang W
Liver Int; 2015 Mar; 35(3):834-45. PubMed ID: 24814578
[TBL] [Abstract][Full Text] [Related]
13. Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127low T cells in parallel with inhibiting hepatitis B virus DNA.
Yan Z; Zhou J; Zhang M; Fu X; Wu Y; Wang Y
Mol Med Rep; 2014 May; 9(5):2024-30. PubMed ID: 24626572
[TBL] [Abstract][Full Text] [Related]
14. [Alterations of IFN-γ and IL-4 of peripheral blood T cells in patients with chronic HBV infection].
Li M; Sun X; Zhou Z; Zhang X; Jin S; Gao Y; Gao Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Feb; 32(2):240-4. PubMed ID: 26927386
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.
Li Y; Zhang Y; Wang JP; Lian JQ; Bai XF
J Viral Hepat; 2013 Apr; 20 Suppl 1():46-51. PubMed ID: 23458524
[TBL] [Abstract][Full Text] [Related]
16. Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir.
Zhao PW; Jia FY; Shan YX; Ji HF; Feng JY; Niu JQ; Ayana DA; Jiang YF
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):190-6. PubMed ID: 23278368
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections.
Gan W; Li J; Zhang C; Chen X; Lin C; Gao Z
BMC Infect Dis; 2020 Dec; 20(1):931. PubMed ID: 33287722
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.
Lv GC; Ma WJ; Ying LJ; Jin X; Zheng L; Yang YD
World J Gastroenterol; 2010 Aug; 16(32):4095-9. PubMed ID: 20731026
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study.
Yan Z; Qiao B; Zhang H; Wang Y; Gou W
Medicine (Baltimore); 2018 Aug; 97(31):e11716. PubMed ID: 30075577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
